Advances in Ion Channel Drug Discovery by donnayoung5

VIEWS: 33 PAGES: 2

More Info
									    Advances in Ion Channel Drug Discovery

    Approximately 13% of approved drugs have mechanisms involving the modulation of ion
    channel activity, which makes ion channels the second-largest mechanistic class of
    marketed compounds. Currently approved drugs address important disease areas including
    diabetes, epilepsy, hypertension, cardiac arrhythmia, anxiety, and pain.

    Approximately 35% of agents in development have big pharma sponsorship, with the
    remaining 65% under development by smaller biotech. CNS indications account for 45% of
    development programs. Agents in late-stage development include several first-in-class
    agents acting at the cystic fibrosis transmembrane regulator, and new NMDA and AMPA
    antagonists.

    Earlier-stage programs focus on selective Nav blockers (following on from genetic validation
    of Nav1.7 involvement in pain), subtype-selective NMDA and AMPA blockers, and a large
    number of TRP family members for a variety of indications.

    Request a Sample for or Inquire before buying the report Ion Channel Drug
    Discovery

    Features and benefits


   Understand the competitive landscape in ion channel modulation and compare the pipelines
    of specialist companies operating in this area
   Identify the most promising targets from a "likelihood of success" viewpoint.
   Identify the targets with scope for ion channel intervention and major market opportunity.
   Understand which advances in target discovery, technology, and clinical development will
    have biggest impact to move the area forward.
   Benchmark available technologies against the gold standard for ion channel discovery.


    Major points covered in Table of Contents of this report include:

    EXECUTIVE SUMMARY

    Introduction

    Characteristics of ion channels

    Commercial exploitation

    Discovery approaches

    New opportunities
Specialist company profiles

Outlook

Appendix

List of Tables

List of Figures

Report Details:
Published: March 2012
No. of Pages: 194
Price: Single User License – US$3835         Corporate User License – US$14381




Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/

Connect With Us:

								
To top